Response by domain (N = 51)
| . | Involved, n (%) . | Complete, n (%) . | Partial, n (%) . | Stable, n (%) . | Worse, n (%) . | Response rate, % (95% CI)* . |
|---|---|---|---|---|---|---|
| Rash/lichenoid changes | 40 (78) | 13 (33) | 7 (17) | 10 (25) | 10 (25) | 50 (36-64) |
| Sclerosis | 27 (53) | 11 (41) | 5 (18) | 6 (22) | 5 (19) | 59 (42-75) |
| Oral | 30 (59) | 9 (30) | 8 (27) | 7 (23) | 6 (20) | 57 (40-72) |
| Fasciitis | 7 (14) | 2 (29) | 1 (14) | 2 (29) | 2 (29) | 43 (18-71) |
| Joint | 20 (39) | 5 (25) | 4 (20) | 5 (25) | 6 (30) | 45 (27-64) |
| Liver | 5 (10) | 0 | 0 | 2 | 3 | 0 |
| Lung | 2 (4) | 0 | 0 | 1 | 1 | 0 |
| Gastrointestinal | 21 (41) | 8 (38) | 1 (5) | 7 (33) | 5 (24) | 43 (25-62) |
| Ocular | 28 (55) | 5 (18) | 2 (7) | 13 (46) | 8 (29) | 25 (13-41) |
| . | Involved, n (%) . | Complete, n (%) . | Partial, n (%) . | Stable, n (%) . | Worse, n (%) . | Response rate, % (95% CI)* . |
|---|---|---|---|---|---|---|
| Rash/lichenoid changes | 40 (78) | 13 (33) | 7 (17) | 10 (25) | 10 (25) | 50 (36-64) |
| Sclerosis | 27 (53) | 11 (41) | 5 (18) | 6 (22) | 5 (19) | 59 (42-75) |
| Oral | 30 (59) | 9 (30) | 8 (27) | 7 (23) | 6 (20) | 57 (40-72) |
| Fasciitis | 7 (14) | 2 (29) | 1 (14) | 2 (29) | 2 (29) | 43 (18-71) |
| Joint | 20 (39) | 5 (25) | 4 (20) | 5 (25) | 6 (30) | 45 (27-64) |
| Liver | 5 (10) | 0 | 0 | 2 | 3 | 0 |
| Lung | 2 (4) | 0 | 0 | 1 | 1 | 0 |
| Gastrointestinal | 21 (41) | 8 (38) | 1 (5) | 7 (33) | 5 (24) | 43 (25-62) |
| Ocular | 28 (55) | 5 (18) | 2 (7) | 13 (46) | 8 (29) | 25 (13-41) |
CI indicates confidence interval.
Response rate included CR + PR.